Population-based study on use of chemotherapy in men with castration resistant prostate cancer

References

• Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–12.
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–20.
   PubMed Web of Science ®Google Scholar
• Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.Eur Urol 2011;59:572–83.
   PubMed Web of Science ®Google Scholar
• Fossa SD, Jacobsen AB, Ginman C, Jacobsen IN, Overn S, Iversen JR, et al. Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: A randomized phase II study. Eur Urol 2007;52:1691–8.
   PubMed Web of Science ®Google Scholar
• Berthold DR, Pond GR, de Wit R, Eisenberger M, Tannock IF. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 2008;19;1749–53.
   PubMed Web of Science ®Google Scholar
• Seruga B, Tannock IF. Chemotherapy-based treatment for castration-resistant prostate cancer. J Clin Oncol 2011;29: 3686–94.
   PubMed Web of Science ®Google Scholar
• Chin SN, Wang L, Moore M, Sridhar SS. A review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital. Curr Oncol 2010;17:24–9.
   PubMed Web of Science ®Google Scholar
• Berruti A, Dogliotti L, Bitossi R, Fasolis G, Gorzegno G, Bellina M, et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: Predictive role of bone resorption and formation markers evaluated at baseline. J Urol 2000; 164:1248–53.
   PubMed Web of Science ®Google Scholar
• Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: A systematic review. Int J Clin Pract 2011;65:1180–92.
   PubMed Web of Science ®Google Scholar
• Harris V, Lloyd K, Forsey S, Rogers P, Roche M, Parker C. A population-based study of prostate cancer chemotherapy. Clin Oncol (R Coll Radiol) 2011;23:706–8.
   PubMed Web of Science ®Google Scholar
• Van Hemelrijck M, Wigertz A, Sandin F, Garmo H, Hellstrom K, Fransson P, et al. Cohort Profile: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. Int J Epidemiol E-pub 2012 May 4.
   Google Scholar
• Mohler J, Bahnson RR, Boston B, Busby JE, D’Amico A, Eastham JA, et al. NCCN clinical practice guidelines in oncology: Prostate cancer. J Natl Compr Canc Netw 2010;8: 162–200.
   PubMed Web of Science ®Google Scholar
• Godtman R, Holmberg E, Stranne J, Hugosson J. High accuracy of Swedish death certificates in men participating in screening for prostate cancer: A comparative study of official death certificates with a cause of death committee using a standardized algorithm. Scand J Urol Nephrol 2011;45:226–32.
   PubMed Web of Science ®Google Scholar
• Fall K, Stromberg F, Rosell J, Andren O, Varenhorst E. Reliability of death certificates in prostate cancer patients. Scand J Urol Nephrol 2008;42:352–7.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40:373–83.
   PubMedGoogle Scholar
• Berglund A, Garmo H, Tishelman C, Holmberg L, Stattin P, Lambe M. Comorbidity, treatment and mortality: A population based cohort study of prostate cancer in PCBaSe Sweden. J Urol 2011;185:833–9.
   PubMed Web of Science ®Google Scholar
• Jellvert A, Lissbrant IF, Edgren M, Ovferholm E, Braide K, Olvenmark AM, et al. Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer. Exp Ther Med 2011;2: 579–84.
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2010;16:203–11.
   PubMed Web of Science ®Google Scholar
• Sorbye H, Pfeiffer P, Cavalli-Bjorkman N, Qvortrup C, Holsen MH, Wentzel-Larsen T, et al. Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer 2009;115:4679–87.
   PubMed Web of Science ®Google Scholar
• van der Pool AE, Damhuis RA, Ijzermans JN, de Wilt JH, Eggermont AM, Kranse R, et al. Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: A population-based series. Colorectal Dis 2012; 14:56–61.
   PubMed Web of Science ®Google Scholar
• Song X, Zhao Z, Barber B, Gregory C, Wang PF, Long SR. Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics. Curr Med Res Opin 2011;27:123–30.
   PubMed Web of Science ®Google Scholar
• Morimoto L, Coalson J, Mowat F, O’Malley C. Factors affecting receipt of chemotherapy in women with breast cancer. Int J Womens Health 2010;2:107–22.
   PubMedGoogle Scholar
• Andreis F, Rizzi A, Rota L, Meriggi F, Mazzocchi M, Zaniboni A. Chemotherapy use at the end of life. A retrospective single centre experience analysis. Tumori 2011;97:30–4.
   Google Scholar
• Asola R, Huhtala H, Holli K. Intensity of diagnostic and treatment activities during the end of life of patients with advanced breast cancer. Breast Cancer Res Treat 2006;100: 77–82.
   PubMed Web of Science ®Google Scholar
• Magarotto R, Lunardi G, Coati F, Cassandrini P, Picece V, Ferrighi S, et al. Reduced use of chemotherapy at the end of life in an integrated-care model of oncology and palliative care. Tumori 2011;97:573–7.
   PubMed Web of Science ®Google Scholar
• Schonberg MA, Marcantonio ER, Li D, Silliman RA, Ngo L, McCarthy EP. Breast cancer among the oldest old: Tumor characteristics, treatment choices, and survival. J Clin Oncol 2010;28:2038–45.
   PubMed Web of Science ®Google Scholar
• Dotan E, Browner I, Hurria A, Denlinger C. Challenges in the management of older patients with colon cancer. J Natl Compr Canc Netw 2012;10:213–24.
   PubMed Web of Science ®Google Scholar
• Anderson J, Van Poppel H, Bellmunt J, Miller K, Droz JP, Fitzpatrick JM. Chemotherapy for older patients with prostate cancer. BJU Int 2007;99:269–73.
   PubMed Web of Science ®Google Scholar
• Aapro MS. Management of advanced prostate cancer in senior adults: The new landscape. Oncologist 2012;17(Suppl 1): 16–22.
   PubMed Web of Science ®Google Scholar
• Italiano A, Ortholan C, Oudard S, Pouessel D, Gravis G, Beuzeboc P, et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol 2009;55:1368–75.
   PubMed Web of Science ®Google Scholar
• Yellen SB, Cella DF, Leslie WT. Age and clinical decision making in oncology patients. J Natl Cancer Inst 1994;86:1766–70.
   PubMed Web of Science ®Google Scholar
• Droz JP, Balducci L, Bolla M, Emberton M, Fitzpatrick JM, Joniau S, et al. Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol 2010;73:68–91.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick JM. Optimizing the management of prostate cancer in senior adults: Call to action. Oncologist 2012; 17(Suppl 1):1–3.
   PubMed Web of Science ®Google Scholar
• Myrdal G, Lamberg K, Lambe M, Stahle E, Wagenius G, Holmberg L. Regional differences in treatment and outcome in non-small cell lung cancer: A population-based study (Sweden). Lung Cancer 2009;63:16–22.
   PubMed Web of Science ®Google Scholar
• Berglund A, Garmo H, Robinson D, Tishelman C, Holmberg L, Bratt O, et al. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer. Eur J Cancer 2012;48:75–84.
   PubMed Web of Science ®Google Scholar
• Cavalli-Bjorkman N, Lambe M, Eaker S, Sandin F, Glimelius B. Differences according to educational level in the management and survival of colorectal cancer in Sweden. Eur J Cancer 2011;47:1398–406.
   PubMed Web of Science ®Google Scholar
• Eaker S, Halmin M, Bellocco R, Bergkvist L, Ahlgren J, Holmberg L, et al. Social differences in breast cancer survival in relation to patient management within a National Health Care System (Sweden). Int J Cancer 2009;124:180–7.
   PubMed Web of Science ®Google Scholar